Imunon, Inc. (IMNN)
NASDAQ:IMNN
Want to see IMNN full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.99Last Year’s EPS
-1.87Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized strong, potentially transformative clinical data (a ~14.7-month median OS benefit from OVATION II), clear enrollment momentum and favorable safety/translation signals, supported by an active plan to present additional data and to pursue investor-friendly financing. Counterbalancing these positives are a challenging capital market, a materially prolonged Phase III enrollment and readout timeline (last patient expected Q1 2029), and increased near-term cash burn driven by trial start-up costs. Management has outlined a restructuring and creative financing approach to conserve cash and limit dilution, and investor interest appears constructive. Overall, the clinical progress and enrollment momentum materially support upside potential, while financing and timeline risks remain meaningful near-term headwinds.Company Guidance
Robust Phase II Overall Survival Benefit
Final OVATION II Phase II data showed a clinically meaningful median overall survival benefit of ~14.7 months for IMNN-001 plus standard-of-care chemotherapy versus control (management noted the observed treatment effect grew from an earlier ~11 months to nearly 15 months across data refreshes).
Phase III (OVATION III) Progressing On Track
Pivotal OVATION III is advancing: 500-patient trial, management expects to randomize ~80 patients in the near term (management cited a target to randomize ~80 patients by end of 2027 and said ~80 patients should be enrolled approximately one year from the call) and projects last patient in Q1 2029; enrollment is progressing and sites are being activated to accelerate recruitment.
Favorable Safety and Mechanism Profile
IMNN-001 demonstrates localized IL-12 delivery with negligible systemic exposure, favorable tolerability, consistent clean safety data across OVATION II and ongoing MRD study, and translational signals of innate and adaptive immune activation that are predictive of superior outcomes.
Strong Investigator and Site Engagement / Enrollment Momentum
Investigators proactively approaching the company, early sites (including OVATION II sites) enrolling above assumptions in some cases, and management reports that sites are performing well with enthusiastic physician engagement driving faster-than-forecast enrollment at early sites.
Planned R&D Day and Upcoming Data Presentations
Company plans an R&D Day in Q3 2026 to present the final OVATION II efficacy analysis and additional translational/MRD data, which could support program visibility and partner/investor interest.
Strategic Financing and Cost Discipline
Management is pursuing a multipronged bridge financing strategy aimed at advancing OVATION III while minimizing dilution (including creative structures such as non-tradable preferred shares without warrants) and completed a strategic reorganization to sharpen focus on OVATION III and extend runway.
Key Q1 Financial Metrics and Guidance
Q1 2026 R&D expenses were $2.3M versus $2.2M a year ago (+~4.6% YoY). General & administrative expenses were reported as $22.0M in Q1 2026, unchanged from Q1 2025 (0% YoY). Net cash used in operating activities was $4.0M in Q1 2026 versus $2.8M prior year (+~42.9%), driven largely by OVATION III start-up costs. Management projects near-term quarterly G&A run-rate post-reorganization of approximately $4.5M–$5.0M.
IMNN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
IMNN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 12, 2026 | $2.73 | $2.70 | -1.10% |
Mar 31, 2026 | $2.88 | $2.94 | +2.08% |
Nov 13, 2025 | $3.95 | $4.16 | +5.32% |
Aug 05, 2025 | $8.00 | $7.62 | -4.78% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Imunon, Inc. (IMNN) report earnings?
Imunon, Inc. (IMNN) is schdueled to report earning on Aug 06, 2026, TBA (Confirmed).
What is Imunon, Inc. (IMNN) earnings time?
Imunon, Inc. (IMNN) earnings time is at Aug 06, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IMNN EPS forecast?
IMNN EPS forecast for the fiscal quarter 2026 (Q2) is -0.99.